Webinar Speaker:
Mariano Barbacid, PhD
About This Webinar:
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis due to late diagnosis and limited treatments, primarily relying on old cytotoxic drugs.
Despite advances in understanding PDAC biology—driven by KRAS mutations and tumor suppressor loss—KRAS inhibitors like Sotorasib (Cat.NO.: HY-114277) have shown limited efficacy, with rapid resistance. Instead of targeting KRAS directly, a novel approach combines inhibition of downstream (RAF1), upstream (EGFR), and orthogonal (STAT3) signaling nodes.
In mouse models, this triple-targeting strategy induced durable tumor regression without significant toxicity. Pharmacological validation is underway, offering potential for improved PDAC therapies.
Webinar Detail:
- Wednesday, May 28, 2025
- 10:00 EDT / 15:00 BST / 16:00 CEST
- Badges
- Science method